Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 30,971 shares of the biopharmaceutical company's stock after selling 8,026 shares during the quarter. Alnylam Pharmaceuticals makes up approximately 0.8% of China Universal Asset Management Co. Ltd.'s portfolio, making the stock its 22nd biggest position. China Universal Asset Management Co. Ltd.'s holdings in Alnylam Pharmaceuticals were worth $8,363,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Larson Financial Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in Alnylam Pharmaceuticals during the 4th quarter worth $28,000. Whipplewood Advisors LLC lifted its position in Alnylam Pharmaceuticals by 208.8% in the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 71 shares during the last quarter. Bessemer Group Inc. boosted its stake in Alnylam Pharmaceuticals by 176.9% in the first quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock valued at $29,000 after acquiring an additional 69 shares in the last quarter. Finally, OFI Invest Asset Management purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $35,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 31,640 shares of the business's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $304.39, for a total transaction of $9,630,899.60. Following the sale, the chief executive officer owned 48,948 shares of the company's stock, valued at $14,899,281.72. The trade was a 39.26% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

Several analysts have recently weighed in on ALNY shares. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Chardan Capital lifted their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Citigroup increased their price objective on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a report on Friday, March 21st. Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a report on Monday, March 31st. They issued a "buy" rating and a $353.00 target price on the stock. Finally, Wells Fargo & Company increased their price target on shares of Alnylam Pharmaceuticals from $287.00 to $333.00 and gave the stock an "equal weight" rating in a research note on Monday, June 30th. One analyst has rated the stock with a sell rating, three have given a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $340.00.

Alnylam Pharmaceuticals Stock Up 0.7%

Alnylam Pharmaceuticals stock opened at $331.94 on Monday. The stock's 50 day moving average price is $294.96 and its 200 day moving average price is $266.45. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $340.65. The company has a market cap of $43.28 billion, a PE ratio of -158.82 and a beta of 0.23. The company has a debt-to-equity ratio of 8.88, a current ratio of 3.04 and a quick ratio of 2.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analysts' expectations of $584.32 million. Alnylam Pharmaceuticals had a negative return on equity of 510.31% and a negative net margin of 11.49%. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.16) earnings per share. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.